Drug recall
BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca…
FDA recall event 77336 · Class I · AstraZeneca Pharmaceuticals, LP
Key facts
| Event ID | 77336 |
|---|---|
| Recall numbers | D-0958-2017 |
| Recalling firm | AstraZeneca Pharmaceuticals, LP |
| Product type | Drugs |
| Products | BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden… |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Firm Initiated |
| Reason for recall | Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8… |
| Initiation date | May 25, 2017 |
| Report date | Jul 19, 2017 |
| Termination date | Apr 24, 2018 |
| City | Newark |
| State | DE |
| Country | United States |
| FEI number | 2517100 |
At a glance
- 1–9 Products in this recall
- 10–99 FDA inspections of this firm (FEI)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug and product recalls
FDA enforcement reports list recalls of drugs, biologics, foods and other FDA-regulated products, classified by the potential health hazard.
Source: U.S. Food and Drug Administration (FDA), Enforcement Reports · Source date: